Navigation Links
ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver

- Phase 1b Combination Data Highlight Favorable Tolerability and Additive Antiviral Activity of HCV-796 -

EXTON, Pa., April 13, 2007 /PRNewswire-FirstCall/ -- ViroPharma Incorporated today announced additional data from a Phase 1b study of HCV- 796, a unique, orally dosed hepatitis C virus (HCV) polymerase inhibitor at the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL). This meeting is being held in Barcelona, Spain. These data on the antiviral activity and tolerability of twice daily HCV-796 in combination with pegylated interferon alfa-2b (peg-IFN) elaborate on previously presented data. HCV-796 is currently undergoing Phase 2 evaluation and is being co-developed with Wyeth Pharmaceuticals, a division of Wyeth .

These Phase 1b combination data demonstrate the additive antiviral effects of HCV-796 across multiple genotypes of hepatitis C virus, in treatment-naïve adult subjects with chronic hepatitis C infection. HCV-796 dosed twice daily plus peg-IFN displays clinical antiviral activity that is greater than that of HCV-796 or peg-IFN alone across all dose cohorts and tested HCV genotypes. Final safety and tolerability data show that HCV-796 is generally well tolerated when added to peg-IFN. Adverse events were generally consistent with known effects of interferons. No dose-limiting toxicities were observed across the range of HCV-796 study doses.

"In this Phase 1b study, HCV-796 provided added antiviral activity to that of pegylated interferon across multiple HCV genotypes and did so largely without altering interferon's tolerability profile," commented Colin Broom, ViroPharma's chief scientific officer. "The adverse events observed in patients on combination therapy were typical of those seen in patients on pegylated interferon alone. The antiviral activity of HCV-796, its strong tolerability profile, and its lack of dose limiting toxicities encou
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:8/28/2015)... Aug. 28, 2015 ... the addition of the "Investigation Report on ... offering. Developed by Pharmacia & Upjohn ... agonist which effectively reduces intraocular pressure. As the ... (under the trade name of Xalatan) entered ...
(Date:8/28/2015)... -- IP Shakti, LLC, today announced that it has changed its ... Logo - http://photos.prnewswire.com/prnh/20150827/261551LOGO ... signifies our transformation into a company focused on patent claim ... claim validity." ... platform, the Company commenced a corporate re-branding initiative in order ...
(Date:8/28/2015)... LOS ANGELES , FARUM, Denmark ... -- On July 31, 2015 the US Food ... for the treatment of Major Depressive Disorder in adult patients ... medication in the current episode. TMS is a non-invasive technique ... implicated in patients suffering from Major Depressive Disorder. The procedure ...
Breaking Medicine Technology:China Latanoprost Market Investigation Report 2015-2019 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3
(Date:8/29/2015)... ... August 29, 2015 , ... Next weekend is Labor Day ... astronomically, officially ends on September 22nd this year). For IT security personnel, it should ... on which could prove far more costly than a simple headache. , Joe Caruso, ...
(Date:8/29/2015)... ... August 29, 2015 , ... The popular television program VOICES IN AMERICA, ... that it will be devoting an entire short segment to the subject of diabetes. ... the globe on a daily basis, but recent advancements in medical science may prove ...
(Date:8/28/2015)... Las Vegas, Nevada (PRWEB) , ... August 28, 2015 , ... ... is announcing its decision to make the purchase of CPAP equipment more affordable by ... This offer includes all types of CPAP products and orders of any size. My ...
(Date:8/28/2015)... ... ... With the goal of furthering music education programs in schools, the “Music With ... in Mendon, IL on May 30th, 2015. Backed once again by Best Drug Rehabilitation, ... school districts of Mendon and its neighboring town of Quincy, IL. Best Drug Rehabilitation’s ...
(Date:8/28/2015)... ... August 28, 2015 , ... The 6th Annual ... Brain Aneurysm Foundation has added yet another accolade to its cadre of widespread support—an ... , “With the help of the medical community and the University of Illinois ...
Breaking Medicine News(10 mins):Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:My Cpap Store Now Offering Delivery Special 0 Cost to You 2Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3
... for diabetic patients.Tiny particles called PM10s, an important component ... and heart problems. Researchers in the US looked at ... 1994 and have uncovered a link between PM10 exposure ... ,PM10s increase the risk of heart rate variability , ...
... Alzheimer's Disease as people who have never smoked, according to ... kind and the first major research to look at people ... aged 57 and over. ,None of the people ... study by the Erasmus Medical School in Rotterdam began.Over a ...
... A new study shows that cells exposed to high doses of ... binding and release of oxygen by red blood cells and iron ... women and older people with a poor diet. That is why ... everyone gets enough of this important mineral.// ,But too ...
... world's largest diabetes epidemic is threatening India, which is ill-equipped ... adult-onset diabetes in Indian cities is high, and rising, suggests ... billion, and its citizens appear prone to developing diabetes later ... such as high blood pressure leading to coronary heart disease. ...
... on how depression worsens the outlook in heart disease.,Mounting evidence ... Washington University School of Medicine now have a new clue ... health of your heart. They followed a subset of participants ... looks at the outcome of a large number of heart ...
... heart attack victims by quickly giving blood transfusions to those ... said this advice, if widely adopted, could save thousands of ... important as giving aspirin, beta blockers or clot-dissolving drugs, which ... ,The size of the benefit depends on how anemic ...
Cached Medicine News:Health News:Diabetes on the rise, 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: